WilmerHale client Precision BioSciences, Inc., a leader in the field of genome engineering, has won a patent infringement lawsuit against Cellectis SA. A jury in the United States District Court for the District of Delaware found that all of the claims of Cellectis’ U.S. Pat. No. 7,897,372 (“the ‘372 patent”) that were asserted against Precision are invalid and that Precision did not literally infringe the asserted claims.
This litigation was the third infringement action brought by Cellectis against Precision since 2008. To date, every patent claim asserted by Cellectis against Precision has been (a) held invalid by a US District Court judge, (b) found invalid by a jury in a US District Court trial, (c) held invalid by the US Patent and Trademark Office, or (d) dismissed by Cellectis in the relevant litigation.
Throughout these proceedings, Precision has been represented by WilmerHale. Partner Michael Twomey has been lead counsel for Precision’s patent prosecution and offensive reexamination proceedings, while Partners Dave Bassett and Vinita Ferrera served as lead counsel in all three of the defensive litigations, including the ‘372 litigation.